Spread of
            <i>Escherichia coli</i>
            Strains with High-Level Cefotaxime and Ceftazidime Resistance between the Community, Long-Term Care Facilities, and Hospital Institutions

Oteo, Jesús; Navarro, Carmen; Cercenado, Emilia; Delgado‐Iribarren, Alberto; Wilhelmi, Isabel; Orden, Beatriz; Garćıa, C.; Migueláñez, Silvia; Pérez-Vázquez, Marı́a; García-Cobos, Silvia; Aracil, Belén; Bautista, Verónica; Campos, José

doi:10.1128/jcm.00447-06

Cited by 185 publications

(128 citation statements)

References 30 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Downstream of four out of six bla CTX-M-14 genes (14, 12, 8, and 21), an IS903-like element was found as already described for this gene (24). ISEcp1 was not identified upstream of the bla CTX-M-2 and bla CTX-M-9 genes, as previously reported (21). ISCR1 was found in isolates harboring bla CTX-M-2 and bla CTX-M-9 genes (Fig.…”

Section: Epidemiology and Pcr Detection Of ␤-Lactamase Genessupporting

confidence: 64%

See 1 more Smart Citation

Extended-Spectrum β-Lactamases of the CTX-M Type Now in Switzerland

Lartigue

Zinsius

Wenger

et al. 2007

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The epidemiology of clavulanic acid-inhibited extended-spectrum ␤-lactamases (ESBLs) was investigated among infection-associated enterobacterial isolates at the University Hospital in Lausanne, Switzerland, from January 2004 to June 2005. Out of 57 nonrepetitive ESBL producers (prevalence rate of 0.7%), 45 produced CTX-M-like ESBLs. CTX-M enzymes were mostly from clonally nonrelated Escherichia coli isolates, from urinary infections and community-acquired infections. Pediatric patients (20 out of 57) accounted for a large number of CTX-M producers. CTX-M-15 was the most frequent CTX-M-type enzyme. The plasmid-located bla CTX-M genes were associated with either ISEcp1 or ISCR1 insertion sequences. This study is the first published report of CTX-M-type ␤-lactamases in Switzerland.Plasmid-mediated extended-spectrum ␤-lactamases (ESBLs) were first identified in a Klebsiella pneumoniae isolate in Germany in 1983 (14). Since then, ESBL-positive Enterobacteriaceae have been isolated worldwide mostly from hospitalized patients (18). These enzymes hydrolyze significantly expandedspectrum cephalosporins such as cefotaxime and ceftazidime and the monobactam aztreonam, sparing carbapenems. Their activity is inhibited in vitro by clavulanic acid. Until the 2000s, most of the ESBLs were structurally related to the narrowspectrum TEM-and SHV-type ␤-lactamases, with one to several amino acid substitutions surrounding their active site (18). Beginning in the late 1990s, novel types of ESBLs, the CTX-M enzymes, emerged worldwide, mostly from Escherichia coli. The CTX-Ms are mostly from community-acquired isolates (2,22). The over 50 CTX-M enzymes so far reported may be grouped into five main subgroups according to amino acid sequence identity (CTX-M-1, -M-2, -M-8, -M-9, and -M-25) (2). Most of the CTX-Ms hydrolyze cefotaxime better than ceftazidime. However, several CTX-Ms including CTX-M-15 (2, 12, 25), which is now the most widespread CTX-M enzyme worldwide (6), hydrolyze ceftazidime efficiently (25).Since those CTX-Ms are reported increasingly in France (8,15,17,26), Italy (4,20), and recently Austria (9), it was interesting to search for those enzymes in Switzerland, a country known to have a strict policy of antibiotic prescription and to have an overall low level of multidrug resistance in bacteria (10).The aim of the present study was to estimate the prevalence and the type of the ESBLs produced by enterobacterial isolates among nonrepetitive clinical isolates over an 18-month period from January 2004 to June 2005 at the University Hospital of Lausanne, Switzerland. MATERIALS AND METHODSBacterial isolates. ESBL-producing enterobacterial isolates resulted from the screening of 8,259 enterobacterial isolates obtained from infection samples that were sent to the Department of Microbiology of the Lausanne University Hospital, Switzerland, from January 2004 to June 2005. Isolates were first identified by using the Vitek2 system (bioMérieux SA, Marcy-l'Etoile, France). Electrocompetent E. coli TOP10 (Invitrogen, Cergy Pontoise, ...

show abstract

Section: Epidemiology and Pcr Detection Of ␤-Lactamase Genessupporting

confidence: 64%

“…PFGE analysis showed that the spread of bla CTX-M -positive E. coli and K. pneumoniae isolates was not related to the spread of single clones as reported in several studies from other countries (United Kingdom, France, Italy, and Spain) (8,20,21,29).…”

Section: Discussionmentioning

confidence: 63%

Extended-Spectrum β-Lactamases of the CTX-M Type Now in Switzerland

Lartigue

Zinsius

Wenger

et al. 2007

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…The presence of bla CTX-M-15 has previously been associated with E. coli strains of phylogroups B2 and D, and in some instances, with specifi c PFGE types (9)(10)(11)(12)16). We detected an emerging and globally disseminated CTX-M-15 phylogroup B2 E. coli strain corresponding to the ST131 that was responsible for clonal outbreaks in Canada, France, Spain, and Portugal (11,14,16,23). Other CTX-M-15 B2 strains belong to clonal complexes ST695, ST405, ST354, or ST28, which have previously been detected in different geographic areas among isolates that do not express CTX-M-15 (online Appendix Figure, available from www.cdc.gov/EID/content/14/2/195-appG.htm).…”

Section: Discussionmentioning

confidence: 87%

“…Although the isolates in our study do not belong to clone CgA, they were isolated mainly from urine samples, and an association of ST131 E. coli isolates with urinary tract infections might be inferred. Although most CTX-M-15 isolates studied were recovered from hospitalized patients, these microorganisms are now widely spread in the community setting, including long-term care facilities in the countries from which isolates included in this study originated (2,5,14,33). Our study has increased knowledge of the number of epidemic E. coli clonal complexes causing urinary tract infections.…”

Section: Discussionmentioning

confidence: 93%

Dissemination of Clonally RelatedEscherichia coliStrains Expressing Extended-Spectrum β-Lactamase CTX-M-15

Coque

Novais

Carattoli

et al. 2008

Emerg. Infect. Dis.

663

469

View full text Add to dashboard Cite

show abstract

“…In addition, yersiniabactin is disproportionately associated with antibiotic-resistant strains, including Ͼ90% of strains of the E. coli sequence type 131 (ST131), an alarming pandemic multidrug-resistant (MDR) clonal group (48)(49)(50)(51), and Ͼ60% of respiratory carbapenemase-producing K. pneumoniae strains, compared to 10% of susceptible K. pneumoniae strains (41). Novel antimicrobial agents or vaccines that target yersiniabactin iron transport or other pathogen-associated nutrient acquisition systems may provide an effective strategy to combat the rising surge of antibiotic-resistant common infections.…”

Section: Figmentioning

confidence: 99%

Blocking Yersiniabactin Import Attenuates Extraintestinal Pathogenic Escherichia coli in Cystitis and Pyelonephritis and Represents a Novel Target To Prevent Urinary Tract Infection

et al. 2015

View full text Add to dashboard Cite

The emergence and spread of extended-spectrum beta-lactamases and carbapenemases among common bacterial pathogens are threatening our ability to treat routine hospital-and community-acquired infections. With the pipeline for new antibiotics virtually empty, there is an urgent need to develop novel therapeutics. Bacteria require iron to establish infection, and specialized pathogen-associated iron acquisition systems like yersiniabactin, common among pathogenic species in the family Enterobacteriaceae, including multidrug-resistant Klebsiella pneumoniae and pathogenic Escherichia coli, represent potentially novel therapeutic targets. Although the yersiniabactin system was recently identified as a vaccine target for uropathogenic E. coli (UPEC)-mediated urinary tract infection (UTI), its contribution to UPEC pathogenesis is unknown. Using an E. coli mutant (strain 536⌬fyuA) unable to acquire yersiniabactin during infection, we established the yersiniabactin receptor as a UPEC virulence factor during cystitis and pyelonephritis, a fitness factor during bacteremia, and a surface-accessible target of the experimental FyuA vaccine. In addition, we determined through transcriptome sequencing (RNA-seq) analyses of RNA from E. coli causing cystitis in women that iron acquisition systems, including the yersiniabactin system, are highly expressed by bacteria during natural uncomplicated UTI. Given that yersiniabactin contributes to the virulence of several pathogenic species in the family Enterobacteriaceae, including UPEC, and is frequently associated with multidrug-resistant strains, it represents a promising novel target to combat antibiotic-resistant infections.W idespread and increasing antibiotic resistance among bacterial pathogens that cause some of our most common health care-associated and community-acquired infections is jeopardizing our ability to prevent and treat routine infectious diseases (1). Two pathogens of particular concern are uropathogenic Escherichia coli (UPEC), which causes the majority (80%) of uncomplicated urinary tract infections (UTI) (2), and Klebsiella pneumoniae, a frequent cause of hospital-acquired pneumonia and UTI (3). Without adequate treatment, both UPEC and K. pneumoniae can breach epithelial and endothelial barriers to gain access to the bloodstream, causing life-threatening bacteremia (4). E. coli rates of resistance to fluoroquinolones and third-generation cephalosporins now exceed 50% in 5 of 6 global regions, and similar resistance rates were reported for K. pneumoniae worldwide (5). Unfortunately, the treatment of severe infections caused by these species must rely on carbapenems, the last resort to treat severe community-and hospital-acquired infections (6). Not only are these antibacterial compounds more expensive and less available in resource-constrained settings, but their extended use contributes to the spread of carbapenem-resistant Enterobacteriaceae (CRE), a serious global public health concern (7).Increasing rates of antimicrobial resistance and limited new therapeut...

show abstract

Spread of Escherichia coli Strains with High-Level Cefotaxime and Ceftazidime Resistance between the Community, Long-Term Care Facilities, and Hospital Institutions

Cited by 185 publications

References 30 publications

Extended-Spectrum β-Lactamases of the CTX-M Type Now in Switzerland

Extended-Spectrum β-Lactamases of the CTX-M Type Now in Switzerland

Dissemination of Clonally RelatedEscherichia coliStrains Expressing Extended-Spectrum β-Lactamase CTX-M-15

Blocking Yersiniabactin Import Attenuates Extraintestinal Pathogenic Escherichia coli in Cystitis and Pyelonephritis and Represents a Novel Target To Prevent Urinary Tract Infection

Contact Info

Product

Resources

About